Bispecific Antibodies Market (By Indication: Cancer, Inflammatory & Autoimmune Disorder, Others; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drugstores, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2034
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Bispecific Antibodies Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Bispecific Antibodies Market, by Indication, 2024-2034
8.1.1. Cancer
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Inflammatory & Autoimmune Disorder
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2021-2034)
9.1. Bispecific Antibodies Market, by Distribution Channel, 2024-2034
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Retail Pharmacies
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Drugstores
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Online Pharmacies
9.1.4.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Indication (2021-2034)
10.1.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Indication (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Indication (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Indication (2021-2034)
10.2.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Indication (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Indication (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Indication (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Indication (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Indication (2021-2034)
10.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Indication (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Indication (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Indication (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Indication (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Indication (2021-2034)
10.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Indication (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Indication (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Indication (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Indication (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Indication (2021-2034)
10.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Indication (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Indication (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.1. Adimab, Innovent Biologics, Inc (U.S.)
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Affimed GmbH (China)
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Amgen Inc (Germany
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. AstraZeneca (U.K.)
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Xencor (U.S.)
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Sanofi (France)
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. F. Hoffmann-La Roche Ltd (Switzerland)
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Regeneron Pharmaceuticals Inc (U.S.)
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Eli Lilly (U.S.)
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Pieris Pharmaceuticals, Inc (U.S.)
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample